IndustryCompany release

Amgen third-quarter revenue rises 8% to $10.4bn as denosumab biosimilars hit Prolia

🇺🇸 Amgen Inc (AMGN) · Tue 03 Nov 2026

Growth in Repatha, Evenity, Uplizna, Imdelltra and Tezspire offset sharp declines in Prolia and Xgeva, while Amgen says it continues to engage the FDA on Tavneos.

Amgen reported third-quarter 2026 results on 3 November, with revenue up 8% to $10.4bn. GAAP earnings per share rose to $7.08, from $5.93 in the same period a year earlier.

The company said Repatha, Evenity, Uplizna, Imdelltra and Tezspire all grew strongly. Prolia and Xgeva, by contrast, fell sharply following the launch of denosumab biosimilars, which Amgen identified as the driver of the decline.

Amgen said it continues to engage the US Food and Drug Administration on Tavneos. The summary of the results available to VigiEye gives no further detail on the nature or timing of that engagement.

The company also cited US Medicare Part D price setting as lowering the net selling price of Enbrel. Under the Inflation Reduction Act, Medicare can negotiate prices for selected high-spend drugs, a mechanism now feeding through to company results.

What it means for your team

  • Market-access teams should note that the denosumab biosimilar launches are already producing steep declines in the reference products, Prolia and Xgeva.
  • Medicare Part D price setting is now cited as reducing Enbrel's net selling price, a concrete example of negotiated pricing affecting reported revenue.
  • Regulatory affairs teams should watch for further information on Amgen's FDA engagement over Tavneos, as no specifics were given in the available material.

Company's press release (SEC filing): Amgen Inc ↗

Article written by VigiEye from the official source (Amgen Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →